Denise K Walters
Overview
Explore the profile of Denise K Walters including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
1292
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Wong T, Kita H, Hanson C, Walters D, Arendt B, Jelinek D
PLoS One
. 2013 Jul;
8(7):e70554.
PMID: 23894671
The biology of the malignant plasma cells (PCs) in multiple myeloma (MM) is highly influenced by the bone marrow (BM) microenvironment in which they reside. More specifically, BM stromal cells...
12.
Arlt M, Walters D, Banke I, Steinmann P, Puskas G, Bertz J, et al.
Int J Cancer
. 2011 Nov;
131(5):E804-12.
PMID: 22120774
Osteosarcoma (OS) is the most frequent primary bone tumor. Despite multiagent neoadjuvant chemotherapy, patients with metastatic disease have a poor prognosis. Moreover, currently used chemotherapeutics have severe toxic side effects....
13.
Steinmann P, Walters D, Arlt M, Banke I, Ziegler U, Langsam B, et al.
Cancer
. 2011 Sep;
118(8):2117-27.
PMID: 21935912
Background: Metastasizing osteosarcoma has a mean 5-year survival rate of only 20% to 30%. Therefore, novel chemotherapeutics for more effective treatment of this disease are required. Methods: The antineoplastic activity...
14.
Wu X, Smoley S, Peterson M, Walters D, Arendt B, Nowakowski G, et al.
Br J Haematol
. 2011 Feb;
153(3):402-5.
PMID: 21323871
No abstract available.
15.
Arlt M, Banke I, Walters D, Puskas G, Steinmann P, Muff R, et al.
J Orthop Res
. 2011 Feb;
29(6):938-46.
PMID: 21284029
More effective treatment of patients with metastasizing osteosarcoma (OS) with a mean 5-year survival rate of <20% requires more detailed knowledge on the complex mechanisms of metastasis for the design...
16.
Walters D, Muff R, Langsam B, Born W, Fuchs B
Invest New Drugs
. 2007 Dec;
26(4):289-97.
PMID: 18071634
Curcumin (diferuloylmethane), one of the main components of the Indian spice turmeric, is known to possess potent anti-inflammatory and anti-oxidant properties. In addition, curcumin has also been shown to have...
17.
Tyner J, Walters D, Willis S, Luttropp M, Oost J, Loriaux M, et al.
Blood
. 2007 Nov;
111(4):2238-45.
PMID: 18025156
Despite vast improvements in our understanding of cancer genetics, a large percentage of cancer cases present without knowledge of the causative genetic events. Tyrosine kinases are frequently implicated in the...
18.
Walters D, Muff R, Langsam B, Gruber P, Born W, Fuchs B
Invest New Drugs
. 2007 Apr;
25(4):305-12.
PMID: 17458504
Taurolidine, the active agent of Taurolin, is a broad spectrum anti-biotic that has been used for over 15 years for the treatment of severe surgical infections. Recently, taurolidine has been...
19.
Gu T, Mercher T, Tyner J, Goss V, Walters D, Cornejo M, et al.
Blood
. 2007 Mar;
110(1):323-33.
PMID: 17360941
Activated tyrosine kinases have been frequently implicated in the pathogenesis of cancer, including acute myeloid leukemia (AML), and are validated targets for therapeutic intervention with small-molecule kinase inhibitors. To identify...
20.
Gu T, Goss V, Reeves C, Popova L, Nardone J, MacNeill J, et al.
Blood
. 2006 Sep;
108(13):4202-4.
PMID: 16946300
The 8p11 myeloproliferative syndrome (EMS) is associated with translocations that disrupt the FGFR1 gene. To date, 8 fusion partners of FGFR1 have been identified. However, no primary leukemia cell lines...